X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients

By Rebecca Davison  |    April 27, 2017
As we’ve noted before, incentives to profit under the 340B program are leading to an uneven playing field for providers and may be shifting care to more expensive and less convenient settings in...   Read More

340B Spotlight: Audit findings show importance of increased oversight of 340B program

By Rebecca Davison  |    February 9, 2017
The 340B Drug Discount Program is an important component of the health care safety net, providing help to vulnerable or uninsured patients. However, with great power comes great responsibility,...   Read More

340B Spotlight: Program continues to grow with no end in sight

By Rebecca Davison  |    October 4, 2016
How much is the 340B program growing? Earlier this year, Drug Channels published new 340B purchase data from Apexus, the 340B program’s Prime Vendor.  Apexus’s data show $12 billion of drug sales...   Read More

340B Spotlight: Trends in shifting site of care

By Rachel Licata  |    September 21, 2016
Research has shown once health care services shift from a provider’s office to a hospital, treatment costs for payers and patients increase. One way hospitals drive this site of care shift is...   Read More

340B Spotlight: Retail pharmacies continue to expand the 340B program

By Rebecca Davison  |    August 17, 2016
One area of needed reform in the 340B program is the use of contract pharmacy arrangements. A new analysis by Drug Channels  found more than one-in-four retail, mail and specialty pharmacies in...   Read More

340B Spotlight: New report raises questions about eligibility metric for 340B hospitals

By Karyn Schwartz  |    August 11, 2016
A new report from the Government Accountability Office (GAO) on how hospitals qualify for certain uncompensated care payments raises questions about how a similar eligibility metric is used to...   Read More

340B Spotlight: A look at 340B eligibility and charity care

By Allyson Funk  |    May 17, 2016
Last week the Alliance for Integrity and Reform of 340B (AIR340B)—of which PhRMA is a member—released a new report looking at charity care provided by 340B hospitals. This expands on previous...   Read More

340B Spotlight: Despite access to discounts, many 340B hospitals fail to comply with ACA charity care requirements

By Rebecca Davison  |    April 28, 2016
Late last year, we highlighted a study published in in the New England Journal of Medicine that found many nonprofit hospitals were not complying with the charity care requirements laid out in the   Read More

340B Spotlight: 340B hospitals account for majority of Part B reimbursements

By Allyson Funk  |    February 9, 2016
Once again, new research is pointing to the critical need to reform the 340B program. The latest data, from Berkeley Research Group (BRG), uncovered startling differences in Medicare Part B...   Read More

340B Spotlight: Hospitals report declines in uncompensated care even as more are qualifying for the 340B drug discount program

By Karyn Schwartz  |    February 3, 2016
We previously noted that it is counterintuitive that more hospitals would become eligible for the 340B discount program as the share of uninsured patients these hospitals serve declines due to the...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates